Drug Trial Radar · NCT06299709
A Study To Evaluate the Relative Bioavailability, Food Effect, and Dose Proportionality of a Granule Formulation of Vanzacaftor/Tezacaftor/Deutivacaftor(VNZ/TEZ/D-IVA)
Last checked: Nov 19, 2026Latest source record: Sep 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
34
Actual
Start
Mar 13, 2024
Primary completion
May 23, 2024
Study completion May 23, 2024
Sponsor
- Lead sponsor
- Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
- Sponsor type
- Industry
- First posted
- Mar 8, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the relative bioavailability, food effect, and dose proportionality of a granule formulation of VNZ/TEZ/D-IVA.
Conditions
- Cystic Fibrosis
Interventions
VNZ/TEZ/D-IVADrug
FDC tablet for oral administration.
VNZ/TEZ/D-IVADrug
FDC granules for oral administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Maximum Observed Plasma Concentration (Cmax) of VNZ, TEZ, and D-IVATime frame: Pre-dose up to 288 hours Post-dose
- Part B: Maximum Observed Plasma Concentration (Cmax) of VNZ, TEZ, and D-IVATime frame: Pre-dose up to 384 hours Post-dose
- Part A: Area Under the Concentration Versus Time Curve (AUC) of VNZ, TEZ, and D-IVATime frame: Pre-dose up to 288 hours Post-dose
- Part B: Area Under the Concentration Versus Time Curve (AUC) of VNZ, TEZ, and D-IVATime frame: Pre-dose up to 384 hours Post-dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Celerion, Inc.
Tempe, Arizona
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.